2021 SPARK
Translational Medicine Symposium

The covid-19 vaccine effort of SPARK Global and beyond

Introduction

今年透過SPARK Global我們請到多位致力於疫苗及藥品開發領域的業界專家,與會者可以了解SPARK Global及其對於COVID-19所做的努力,並一窺市面上唯一鼻噴劑型流感四價疫苗FluMist的研發過程,另外本次也會有SPARK Stanford團隊一路成為上市公司Eidos Therapeutics的成長故事,外加曾帶領全球臨床試驗的業師剖析licensing out的挑戰與技巧。期待國內各方產學研界夥伴們一同參與此盛會!

會議時間: 2021/10/25 9:00 - 13:00(Taiwan Time)
會議形式: 線上
** 視訊網址將於會議前3天以email告知.

In the 2021 SPARK Translational Symposium, SPARK Taiwan invites leading industry experts through SPARK Global on vaccines and drugs developments. The contents include SPARK Global and its effort to COVID-19 from Dr. Daria Mochly-Rosen, the development process of FluMist which is the only nasal spray influenza quadrivalent vaccine on the market by Dr. Mark Backer, in the second half, there will be the success story of Dr. Isabella Graef of Eidos Therapeutics leading her SPARK Stanford team from the academic to have a major product, and also licensing out strategy by Dr. Lyn Frumkin, who has led global clinical trials. We look forward to all partners in the industry, academia, and research circles participating in this grand event!

Date: 2021/10/24 18:00 - 22:00(PDT)
Venue: Online
** The video URL will be notified by email 3 days before the symposium.

Agenda

Date:
2021 Oct. 25 9:00-12:20(Taiwan time);
2021 Oct 24 18:00-21:20(PDT)

Venue: ON-LINE

Taiwan Time Topics Speakers
09:00 ~ 9:30

Registration

09:30 ~ 9:40

Opening Remarks

Prof. Y. Jane Tseng
Director, SPARK Taiwan Program STPI, National Applied Research Laboratory
國家實驗研究院科技政策研究與資訊中心 曾宇鳳 教授

9:40 ~ 10:20

Keynote Session-I

SPARK Global & COVID-19 effort

Speaker:

Prof. Daria Mochly-Rosen
Founder and co-Director of SPARK At Stanford,
Professor of Chemical and Systems Biology, Stanford University School of Medicine, California, USA

10:20 ~ 11:00

Keynote Session-II

The development of flu vaccine and Flumist

Speaker:

Dr. Mark Backer
General Manager, Alava Biopharm Partners
Advisor, Stanford SPARK Program in Translational Research

11:00 ~ 11:20

Break

11:20 ~ 12:10

Session I

Development of Small Molecule to Treat Amyloidosis(TBD)

Speaker:

Isabella Graef, MD, PhD
Assistant Professor of Stanford University
Scientific Co-Founder, Eidos Therapeutics

12:10 ~ 13:00

Session II

Biotechnology Opportunities-Assessing Their Attractiveness

Speaker:

Lyn Frumkin, MD, PhD
Advisor, Stanford SPARK Program in Translational Research

13:00

Closing Remarks

Prof. Y. Jane Tseng
Director, SPARK Taiwan Program
STPI, National Applied Research Laboratory

 

Speakers

Daria Mochly-Rosen

Founder and Director of SPARK At Stanford,
Professor of Chemical and Systems Biology, Stanford University School of Medicine, California, USA

Professor Daria Mochly-Rosen helps academics navigate the so-called “valley of death” between drug discovery and development. Professor Mochly-Rosen founded The SPARK Program at Stanford in 2006 after having to leave academia to start a pharmaceutical company to translate her protein kinase C research into cardiovascular therapeutics. Challenging the academic dogma of how scientific discoveries should reach the pharmaceutical industry, the SPARK model has been implemented internationally and has resulted in a book about drug development from academia. Professor of Chemical and Systems Biology at Stanford, she leads a multi-disciplinary research lab that includes chemists, biochemists, biologists and physician scientists. She has published over 285 papers and over 36 patents and patent applications. Professor Mochly-Rosen is originally from Israel, where she received her doctorate in Chemical Immunology from The Weizmann Institute of Science.

Mark Backer.

General Manager, Alava Biopharm Partners
Advisor, Stanford SPARK Program in Translational Research

Dr. Backer is currently the owner and manager of Alava Biopharm Partners, a consulting firm started in 2013 with broad capabilities to support development of biological products including cell and gene therapies. Dr. Backer hasexperience in the development and manufacturing of a wide variety of biopharmaceuticals including antibodies, proteins, viral-based vaccines and cell therapies. He also has business experience as a biotech startup CEO, and was founding chairman of the vector manufacturing firm SAFC Pharma. Dr. Backer’s industry experience began in 1978, when he was the seventh employee of Genentech and initiated its pilot manufacturing operations. He led pioneering efforts in large-scale cell culture technology and ex-vivo expansion and transfection of human stem cells. He also served as CEO of Vaxart (viral-based oral vaccine platform), SVP Technical Operations with Jennerex, VP Technical Development with Protein Design Labs, and previously served in positions of increasing responsibility with firms including Aviron (now MedImmune Vaccines), Systemix, IDEC, and Eli Lilly. Dr. Backer received a PhD in Chemical Engineering from the University of Washington, and a BS in Chemistry from Stanford University.

Isabella Graef, M.D.

Assistant Professor of Stanford University
Scientific Co-Founder, Eidos Therapeutics

Isabella Graef, M.D., is a scientific co-founder of Eidos Therapeutics and a faculty member at Stanford University. Dr. Graef’s medical training, together with her research training at University of California, Berkeley and Stanford, led her to address questions at the intersection of medicine, biology and chemistry. Dr. Isabella Graef developed a screen to search for small molecules capable of stabilizing the Transthyretin(TTR) protein in its native tetramer and preventing aggregation of unstable monomers. Her lab was able to identify a novel small molecule that stabilized both the mutant and wild-type forms of TTR Testing in patient blood showed the molecule prevented monomer dissociation and reduced toxicity of aggregates. SPARK support helped the team to perform oral dosing studies in animals and show superiority of the small molecule lead to other compounds in development for TTR amyloidosis.

Lyn Frumkin

Advisor, Stanford SPARK Program in Translational Research

Lyn Frumkin consults on biotechnology for start-up and early stage biotechnology companies. He previously worked at Amgen Inc. and ICOS Corp., where he provided varying expertise, including leading clinical teams conducting global development programs across multiple therapeutic indications with successful approval of pivotal trials and programs in North America, Europe, and Japan. Lyn received his BS and a combined MD-PhD from the University of Washington. His postgraduate training in internal medicine was at Stanford University, with subsequent subspecialty training in Neurology (UCLA) and Infectious Diseases/Virology (University of Washington).

 

SPARK Taiwan 計畫辦公室

梅永郁 專案副理 | 02-2737-7023 | sparktw@narlabs.org.tw

Copyright © SPARK TAIWAN. All rights reserved.